[1] WANG H,MEN P X,XIAO Y F,et al.Hepatitis B infection in the general population of China:a systematic review and meta-analysis[J]. BMC Infect Dis,2019,19(1):811. [2] 张莉,邱艳. 隐匿性乙型肝炎病毒发生分子机制的研究进展[J]. 中国医药导报,2019,16(17):23-26. [3] 黄敏,白林,卢长春,等. 血站核酸筛查模式对输血传播HBV残余风险影响的评估研究[J]. 中华实验和临床病毒学杂志,2022,36(4):429-435. [4] 王丁丁,沈有华,钟建玲,等. 我国18家地市级血站献血人群HBV感染情况分析[J]. 中国输血杂志,2023,36(2):172-176. [5] LIANG X F,BI S L,YANG W Z,et al.Reprint of: Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination[J]. Vaccine,2013,31:J21-J28. [6] VELATI C,ROMANÒ L,PICCININI V,et al.Prevalence,incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy:a 7-year (2009-2015) survey[J]. Blood Transfus,2018,16(5):422-432. [7] WHO. WHO Expert Committee on Biological Standardization[EB/OL].[2024-07-19]. extension://bfdogplmndidlpjfhoijckpakkdjkkil/pdf/viewer.html?file=https%3A%2F%2Firis.who.int%2Fbitstream%2Fhandle%2F10665%2F255657%2F9789241210133-eng.pdf%3Bjsessionid%3DC6D0170F81E74ACC7DC6986E7A65741C%3Fsequence%3D1. [8] 代华友,万建华,陈玉香,等. 国内23家血液中心全血献血人群基本特征研究[J]. 中国输血杂志,2020,33(11):1122-1127. [9] CORRÊA A S M,LAMARÃO L M,VIEIRA P C M,et al. Prevalence,incidence and residual risk of transfusion-transmitted HBV infection before and after the implementation of HBV-NAT in northern Brazil[J]. PLoS One,2018,13(12):e0208414. [10] GRUBYTE S,URBONIENE J,NEDZINSKIENE L,et al.Prevalence,incidence and residual risk of transfusion transmitted viruses (HBV,HCV and HIV infections) in Lithuanian blood donors from 2004 to 2018:The incidence/window-period model study[J]. PLoS One,2021,16(2):e0246704. [11] STRAMER S L,NOTARI E P,KRYSZTOF D E,et al.Hepatitis B virus testing by minipool nucleic acid testing:does it improve blood safety?[J]. Transfusion,2013,53(10 Pt 2):2449-2458. [12] DODD R Y,CROWDER L A,HAYNES J M,et al.Screening blood donors for HIV,HCV,and HBV at the American red cross:10-year trends in prevalence,incidence,and residual risk,2007 to 2016[J]. Transfus Med Rev,2020,34(2):81-93. [13] WEUSTEN J,VERMEULEN M,VAN DRIMMELEN H,et al.Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms[J]. Transfusion,2011,51(1):203-215. [14] LELIE N,VERMEULEN M,VAN DRIMMELEN H,et al.Direct comparison of three residual risk models for hepatitis B virus window period infections using updated input parameters[J]. Vox Sang,2020,115(3):133-145. [15] YANG H,ANDERSON S A,FORSHEE R,et al.Modeling complete removal of risk assessment questions in the USA predicts the risk of HIV exposure in blood recipients could increase despite the use of nucleic acid testing[J]. Vox Sang,2016,110(4):324-328. [16] AINLEY L I,HEWITT P E.Haematology patients and the risk of transfusion transmitted infection[J]. Br J Haematol,2018,180(4):473-483. [17] O'BRIEN S F,YI Q L,FAN W L,et al. Residual risk of HIV,HCV and HBV in Canada[J]. Transfus Apher Sci,2017,56(3):389-391. [18] BUSCH M P,BLOCH E M,KLEINMAN S.Prevention of transfusion-transmitted infections[J]. Blood,2019,133(17):1854-1864. [19] 胡贵宾,郑艳梅,释艳华. 襄阳地区ELISA+NAT模式降低HBV输血残余风险的效果分析[J]. 临床输血与检验,2018,20(3):273-275. [20] 谈维,英圣艳,成宁,等. 我国血站输血传播相关传染病标记物检测策略现状研究[J]. 中华实验和临床病毒学杂志,2023,37(4):383-388. [21] 吴敬林,周仲民,罗保红. 核酸检测对降低柳州地区输血病原感染残余风险的评估[J]. 中国输血杂志,2014,27(7):727-729. [22] 黄敏,李燕,张立波,等. 南京地区无偿献血人群输血传播HBV残余风险度评估研究[J]. 临床输血与检验,2022,24(4):454-458. [23] 李莉华,何路军,马印图. 石家庄地区输血传播乙型肝炎病毒、丙型肝炎病毒、艾滋病病毒残余风险评估[J]. 中国卫生检验杂志,2016,26(13):1939-1941. [24] 张莉, 车忠民李玉军, 等.2016—2022年我国17家血液中心献血者HBV感染相关标记物检测情况分析[J].北京医学,2024,46(8):688-694. [25] BAGOT K L,MURRAY A L,MASSER B M.How can we improve retention of the first-time donor? A systematic review of the current evidence[J]. Transfus Med Rev,2016,30(2):81-91. |